vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and XPLR Infrastructure, LP (XIFR). Click either name above to swap in a different company.

CLOVER HEALTH INVESTMENTS, CORP. is the larger business by last-quarter revenue ($749.2M vs $249.0M, roughly 3.0× XPLR Infrastructure, LP). XPLR Infrastructure, LP runs the higher net margin — 11.2% vs 3.6%, a 7.6% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (62.0% vs -15.3%). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (45.0% CAGR vs -1.6%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

XPLR Infrastructure is a publicly traded subsidiary of NextEra Energy, is a Juno Beach, Florida-based renewable energy company.

CLOV vs XIFR — Head-to-Head

Bigger by revenue
CLOV
CLOV
3.0× larger
CLOV
$749.2M
$249.0M
XIFR
Growing faster (revenue YoY)
CLOV
CLOV
+77.4% gap
CLOV
62.0%
-15.3%
XIFR
Higher net margin
XIFR
XIFR
7.6% more per $
XIFR
11.2%
3.6%
CLOV
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
45.0%
-1.6%
XIFR

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CLOV
CLOV
XIFR
XIFR
Revenue
$749.2M
$249.0M
Net Profit
$27.3M
$28.0M
Gross Margin
Operating Margin
3.6%
-19.3%
Net Margin
3.6%
11.2%
Revenue YoY
62.0%
-15.3%
Net Profit YoY
124.3%
EPS (diluted)
$0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
XIFR
XIFR
Q1 26
$749.2M
Q4 25
$487.7M
$249.0M
Q3 25
$496.6M
$315.0M
Q2 25
$477.6M
$342.0M
Q1 25
$462.3M
$282.0M
Q4 24
$337.0M
$294.0M
Q3 24
$331.0M
$319.0M
Q2 24
$356.3M
$360.0M
Net Profit
CLOV
CLOV
XIFR
XIFR
Q1 26
$27.3M
Q4 25
$-49.3M
$28.0M
Q3 25
$-24.4M
$-37.0M
Q2 25
$-10.6M
$79.0M
Q1 25
$-1.3M
$-98.0M
Q4 24
$-22.1M
$-115.0M
Q3 24
$-9.2M
$-40.0M
Q2 24
$7.4M
$62.0M
Gross Margin
CLOV
CLOV
XIFR
XIFR
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
24.5%
Q2 24
30.3%
Operating Margin
CLOV
CLOV
XIFR
XIFR
Q1 26
3.6%
Q4 25
-10.1%
-19.3%
Q3 25
-4.9%
1.6%
Q2 25
-2.2%
26.3%
Q1 25
-0.3%
-82.6%
Q4 24
-6.4%
-188.1%
Q3 24
-2.7%
15.4%
Q2 24
2.0%
18.3%
Net Margin
CLOV
CLOV
XIFR
XIFR
Q1 26
3.6%
Q4 25
-10.1%
11.2%
Q3 25
-4.9%
-11.7%
Q2 25
-2.2%
23.1%
Q1 25
-0.3%
-34.8%
Q4 24
-6.6%
-39.1%
Q3 24
-2.8%
-12.5%
Q2 24
2.1%
17.2%
EPS (diluted)
CLOV
CLOV
XIFR
XIFR
Q1 26
$0.05
Q4 25
Q3 25
$-0.40
Q2 25
$0.84
Q1 25
$-1.05
Q4 24
Q3 24
$-0.43
Q2 24
$0.66

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
XIFR
XIFR
Cash + ST InvestmentsLiquidity on hand
$177.6M
$960.0M
Total DebtLower is stronger
$6.2B
Stockholders' EquityBook value
$339.4M
$10.9B
Total Assets
$697.7M
$19.6B
Debt / EquityLower = less leverage
0.57×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
XIFR
XIFR
Q1 26
$177.6M
Q4 25
$78.3M
$960.0M
Q3 25
$711.0M
Q2 25
$880.0M
Q1 25
$1.5B
Q4 24
$194.5M
$283.0M
Q3 24
$288.0M
$290.0M
Q2 24
$254.8M
$281.0M
Total Debt
CLOV
CLOV
XIFR
XIFR
Q1 26
Q4 25
$6.2B
Q3 25
Q2 25
Q1 25
Q4 24
$5.3B
Q3 24
Q2 24
Stockholders' Equity
CLOV
CLOV
XIFR
XIFR
Q1 26
$339.4M
Q4 25
$308.7M
$10.9B
Q3 25
$340.9M
$11.0B
Q2 25
$344.2M
$11.3B
Q1 25
$336.1M
$12.6B
Q4 24
$341.1M
$12.9B
Q3 24
$342.2M
$13.6B
Q2 24
$324.9M
$13.9B
Total Assets
CLOV
CLOV
XIFR
XIFR
Q1 26
$697.7M
Q4 25
$541.0M
$19.6B
Q3 25
$559.7M
$19.1B
Q2 25
$575.0M
$20.5B
Q1 25
$583.7M
$21.4B
Q4 24
$580.7M
$20.3B
Q3 24
$653.0M
$20.9B
Q2 24
$674.2M
$21.7B
Debt / Equity
CLOV
CLOV
XIFR
XIFR
Q1 26
Q4 25
0.57×
Q3 25
Q2 25
Q1 25
Q4 24
0.41×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
XIFR
XIFR
Operating Cash FlowLast quarter
$186.0M
Free Cash FlowOCF − Capex
$-88.0M
FCF MarginFCF / Revenue
-35.3%
Capex IntensityCapex / Revenue
110.0%
Cash ConversionOCF / Net Profit
6.64×
TTM Free Cash FlowTrailing 4 quarters
$-219.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
XIFR
XIFR
Q1 26
Q4 25
$-66.9M
$186.0M
Q3 25
$12.1M
$231.0M
Q2 25
$5.4M
$232.0M
Q1 25
$-16.3M
$90.0M
Q4 24
$34.8M
$283.0M
Q3 24
$50.0M
$208.0M
Q2 24
$44.8M
$231.0M
Free Cash Flow
CLOV
CLOV
XIFR
XIFR
Q1 26
Q4 25
$-69.0M
$-88.0M
Q3 25
$11.4M
$-283.0M
Q2 25
$4.8M
$151.0M
Q1 25
$-16.5M
$1.0M
Q4 24
$33.3M
$231.0M
Q3 24
$49.6M
$152.0M
Q2 24
$44.4M
$162.0M
FCF Margin
CLOV
CLOV
XIFR
XIFR
Q1 26
Q4 25
-14.1%
-35.3%
Q3 25
2.3%
-89.8%
Q2 25
1.0%
44.2%
Q1 25
-3.6%
0.4%
Q4 24
9.9%
78.6%
Q3 24
15.0%
47.6%
Q2 24
12.5%
45.0%
Capex Intensity
CLOV
CLOV
XIFR
XIFR
Q1 26
Q4 25
0.4%
110.0%
Q3 25
0.1%
163.2%
Q2 25
0.1%
23.7%
Q1 25
0.0%
31.6%
Q4 24
0.5%
17.7%
Q3 24
0.1%
17.6%
Q2 24
0.1%
19.2%
Cash Conversion
CLOV
CLOV
XIFR
XIFR
Q1 26
Q4 25
6.64×
Q3 25
Q2 25
2.94×
Q1 25
Q4 24
Q3 24
Q2 24
6.04×
3.73×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLOV
CLOV

Segment breakdown not available.

XIFR
XIFR

Renewable Energy Sales$238.0M96%
Related Party$8.0M3%

Related Comparisons